Cover Image
市場調查報告書

學名藥的全球市場預測 (2017∼2027年)

Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets - US, EU5, Asia-Pacific, Emerging Markets

出版商 Visiongain Ltd 商品編碼 220569
出版日期 內容資訊 英文 304 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
學名藥的全球市場預測 (2017∼2027年) Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets - US, EU5, Asia-Pacific, Emerging Markets
出版日期: 2017年01月18日 內容資訊: 英文 304 Pages
簡介

學名藥市場,預計從2015年到2027年以7.9%的年複合成長率發展,2016年達到2,546億美元,2021年達3,840億美元,2027年達5,747億美元的規模。

本報告提供全球學名藥市場相關調查,市場今後的預測和各地區趨勢,至2027年的收益預測,大企業簡介等彙整資料。

第1章 報告概要

第2章 學名藥的簡介

  • 學名藥的繁榮
  • 所謂學名藥
  • 醫藥品產業概要
  • 生物學同等性的確證
  • 學名藥的種類
  • 合成學名藥
  • 學名藥市場分類
  • 非專利的替代對大規模的醫藥品商務來說是壞消息嗎?
  • 對於學名藥的法律規章
  • 強制授權
  • 市場定義和報告的範圍

第3章 學名藥市場

  • 市場概要
  • 全球市場的擴大
  • 各地區趨勢
  • 銷售額預測
  • 各地區市場的預測
  • 主要市場預測
  • 帶動成長的市場
  • 市場佔有率的變遷
  • 全球市場:促進因素與阻礙因素

第4章 美國的學名藥市場

第5章 歐洲主要國家的學名藥市場

第6章 亞太地區的學名藥市場

第7章 新興學名藥市場

  • 市場概要
  • 巴西
  • 俄羅斯
  • 墨西哥
  • 韓國
  • 土耳其

第8章 學名藥市場上的大企業

  • 持續性擴大
  • Teva
  • Novartis
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi

第9章 學名藥市場定性分析

第10章 專家的意見

第11章 詞彙表

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0162

The generic drugs market is expected to grow at a CAGR of 8.8% in the first half of the forecast period and CAGR of 7.0% in the second half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2015 to 2027. The market is estimated at $254.6bn in 2016, $384.0bn in 2021, and $574.7bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 304-page report you will receive 89 tables and 87 figures- all unavailable elsewhere.

The 303-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Generic Drugs Market forecasts from 2017-2027
  • Generic Drugs National Market forecasts from 2017-2027, covering:
    • United States
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Japan
    • China
    • India
    • Brazil
    • Russia
    • South Korea
    • Turkey
    • Mexico
  • Analysis of the key factors driving and restraining the growth of the generic drugs market from 2017-2027
  • Assessment of selected leading companies that hold major market shares in the generic drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.

Buy our report today Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets - US, EU5, Asia-Pacific, Emerging Markets.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Generic Drugs: Market Overview
  • 1.2. Global Generic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is this Report for?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQs)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. An Introduction to Generic Drugs

  • 2.1. An Introduction to the Rise of Generic Drugs
  • 2.2. What Are Generic Drugs?
    • 2.2.1. Generic Active Ingredients
  • 2.3. A Brief Overview of the Pharmaceutical Industry
    • 2.3.1. Brief History of Generic Drugs
    • 2.3.2. The Hatch-Waxman Act: The Rise of Generics
  • 2.4. Demonstrating Bioequivalence: A Major Factor in Approving Generics
  • 2.5. Types of Generics - Authorised, Branded and Unbranded
  • 2.6. Complex Generics
  • 2.7. Classification of Generic Drugs Markets
  • 2.8. Is Generic Substitution Bad News for Big Pharma Business?
    • 2.8.1. The 'Ever greening' of Pharmaceutical Products
  • 2.9. Regulation of Generic Drugs
    • 2.9.1. Regulation in the US
      • 2.9.1.1. Obtaining FDA Approval: NDAs and ANDAs
      • 2.9.1.2. The Hatch-Waxman Act Title I: Promotion of Generic Drugs
      • 2.9.1.3. The Hatch-Waxman Act Title II: Incentives for the Branded Industry
      • 2.9.1.4. How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?
      • 2.9.1.5. How the Timing of Market Entry Influences Product Success
    • 2.9.2. Regulation in Europe
      • 2.9.2.1. EU Marketing Approval Procedures
      • 2.9.2.2. The 8+2+1 Rule: EU Data Exclusivity
      • 2.9.2.3. Supplementary Protection Certificates
      • 2.9.2.4. Variation in Drug Development Regulations between European Countries
      • 2.9.2.5. The Move towards the Harmonisation of Standards
      • 2.9.2.6. The Impact of Europe's Unitary Patent System on Generic Drugs:
      • 2.9.2.7. In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
    • 2.9.3. Regulation in Japan
    • 2.9.4. Regulation in China
  • 2.10. Compulsory Licensing
  • 2.11. Market Definition and Scope of This Report
    • 2.11.1. Market Sizing and Revenue Reporting
    • 2.11.2. Currency Exchange Rates in This Report

3. Generic Drugs Market, 2017-2027

  • 3.1. The Global Generic Drugs Market: Market Overview
    • 3.1.1. Segmenting the Global Generic Drugs Market
  • 3.2. The Rise of the Global Generic Drugs Market in 2016
  • 3.3. Changes in the Regional Distribution of the Generic Drugs Market 2015-2016
  • 3.4. The Global Generic Drugs Market: Sales Forecast 2017-2027
  • 3.5. Generic Drugs: Regional Market Forecast 2017-2027
    • 3.5.1. Changes in Generic Drug Regional Market Shares 2017-2027
  • 3.6. Leading National Markets for Generic Drugs: Market Forecast 2017-2027
  • 3.7. National Markets that will Drive Generic Drugs Growth
  • 3.8. Changes in Market Shares by National Market, 2017-2027
  • 3.9. Drivers and Restraints for the Global Generic Drugs Market 2017-2027

4. US Generic Drugs Market, 2017-2027

  • 4.1. Generic Drugs in the US: Market Overview
    • 4.1.1. The Effects of Generics on Healthcare Spending in the US
    • 4.1.2. The Hatch-Waxman Act and Its Ongoing Effects
    • 4.1.3. Consolidation in the Drug Development and Supply Chain Driving US Generics
  • 4.2. US Historical Generic Penetration Rates
  • 4.3. Leading Companies Operating within the US Generic Drugs Market
    • 4.3.1. The Increasing Acceptance of Generics amongst Consumers
    • 4.3.2. Affordable Care Act: Expanding Medicare Coverage
  • 4.4. The US Generic Drugs Market: Drivers and Restraints 2017-2027
  • 4.5. The US Generic Drugs Market Forecast: 2017-2027
  • 4.6. The US Generic Drugs Market - Strategic Analysis
    • 4.6.1. Will Biosimilars Dictate the Future of the US Generics Market?
    • 4.6.2. The Backlog of ANDA Applications
    • 4.6.3. The Generic Drug User Fee Amendments (GDUFA)
    • 4.6.4. Shortages of Generic Drugs Will Restrain the Market
    • 4.6.5. The Anti-Competitive ‘Pay for Delay' Effect
  • 4.7. US Generic Drugs Market: A Range of Factors Contributing to Growth

5. Leading European Generic Drugs Market, 2017-2027

  • 5.1. European Generic Drugs: Market Overview
    • 5.1.1. The EU5
    • 5.1.2. Why Growth in Some Markets is Being Hindered?
    • 5.1.3. Predominant Pricing Systems and Generic Penetration in European Markets
      • 5.1.3.1. Lower Patient Co-Payments Drive for Generics
      • 5.1.3.2. The Effects of Tendering for Generic Medicines
    • 5.1.4. Will Europe Move towards Free-Pricing Systems?
    • 5.1.5. Challenges in the European Regulatory Environment
    • 5.1.6. Ending Anti-Competitive ‘Pay for Delay' Tactics in Europe
    • 5.1.7. FDA and EMA Joint Data Sharing and Inspections
  • 5.2. EU5 Generic Drugs Market Forecast: 2017-2027
  • 5.3. EU5 Market Share Breakdown 2017-2027
  • 5.4. Germany: New Reforms to Medicinal Pricing May Impact Market Entry
    • 5.4.1. German Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 5.4.2. German Generic Drugs Market: Generic Penetration by Value, 2001-2016
  • 5.5. UK Generic Drugs Market: A Mature Market with Growth Potential
    • 5.5.1. UK Generic Drugs Market: Sales Forecast 2017-2027
    • 5.5.2. Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
    • 5.5.3. UK Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 5.5.4. UK Generic Drugs Market: Generic Penetration by Value, 2001-2016
    • 5.5.5. Pharmacists as Enforcers of Generic Substitution
    • 5.5.6. Pay Time for ‘Pay-For-Delay'
    • 5.5.7. GSK: Widening the Gate to Accessible Medicines
  • 5.6. French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
    • 5.6.1. French Generic Drugs Market: Sales Forecast 2017-2027
    • 5.6.2. French Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 5.6.3. French Generic Drugs Market: Generic Penetration by Value, 2001-2016
  • 5.7. Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
    • 5.7.1. The Tightening of Italy's Patent Legislations
    • 5.7.2. The Italian Healthcare System - A Tale of Falling Budgets
    • 5.7.3. Italian Generic Drugs Market: Sales Forecast: 2017-2027
    • 5.7.4. Italian Generic Drugs market: Generic Penetration by Volume
    • 5.7.5. Italian Generic Drugs Market: Generic Penetration by Value
  • 5.8. Spanish Generic Drugs Market: Room for Growth
    • 5.8.1. Cost-Containment Measures Helping to Boost Generic Drug Use
    • 5.8.2. Spanish Generic Drugs Market: Sales Forecast 2017-2027
    • 5.8.3. Spanish Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 5.8.4. Spanish Generic Drugs Market: Generic Penetration by Value, 2001-2016

6. Asia-Pacific Generic Drugs Market, 2017-2027

  • 6.1. Generic Drugs in the Asia-Pacific Market: Market Overview
  • 6.2. Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
    • 6.2.1. The Major Drivers of Growth in the Chinese Generics Market
    • 6.2.2. Chinese Generic Drugs Market: Sales Forecast 2017-2027
    • 6.2.3. Compulsory Licensing of Generic Drugs
    • 6.2.4. Expansion of Healthcare Coverage and Reimbursement
    • 6.2.5. Chinese Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 6.2.6. Chinese Generic Drugs Market: Generic Penetration by Value, 2001-2016
    • 6.2.7. The Impacts of Price Controls and the Anhui Model
  • 6.3. Japanese Generic Drugs Market: High Barriers to Entry
    • 6.3.1. Public Perception of Generics in Japan
    • 6.3.2. Japanese Generic Drugs Market: Leading Companies
    • 6.3.3. Japanese Generic Drugs Market: Sales Forecast 2017-2027
    • 6.3.4. Japanese Generic Drugs Market: Generic Penetration by Volume, 2001-2016
    • 6.3.5. Japanese Generic Drugs Market: Generic Penetration by Value, 2001-2016
    • 6.3.6. Government Initiatives Driving Generic Penetration
    • 6.3.7. Japanese Attitudes to Generic Drugs
  • 6.4. Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
    • 6.4.1. Leading Companies in the Indian Generic Drugs Market
    • 6.4.2. Indian Generic Drugs Market: Sales Forecast 2017-2027
    • 6.4.3. The Reforms to India's Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
    • 6.4.4. Expansion of the National Healthcare Coverage Increases the Need for Generics
    • 6.4.5. Has Recent Manufacturing Quality Failures Dented India's Generics Growth?

7. Emerging Generic Drugs Market, 2017-2027

  • 7.1. Generic Drugs in the Emerging Market: Market Overview
    • 7.1.1. Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
  • 7.2. Brazil Generic Drugs Market
    • 7.2.1. Brazilian Generic Drugs Market: Sales Forecast 2017-2027
    • 7.2.2. Generics to Facilitate Low-Income Earner's Access to Medicines
    • 7.2.3. Foreign Generic Drug Manufacturers Entering the Brazilian Market
  • 7.3. Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
    • 7.3.1. Historical Trends in Russia's Pharmaceutical Production and Distribution
    • 7.3.2. The Pharma2020 Strategy - Healthcare and Industry Reform
    • 7.3.3. Self-Medication in Russia and the Integral Role of Pharmacies
    • 7.3.4. Russian Generic Drugs Market: Sales Forecast 2017-2027
  • 7.4. Mexican Generic Drugs Market: Boost by Investment from the Government
    • 7.4.1. Government Programmes to Vitalise Generic Penetration in Mexico
    • 7.4.2. Regulatory Changes and the Inception of COFEPRIS
    • 7.4.3. Mexican Generic Drugs Market: Sales Forecast 2017-2027
  • 7.5. South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
    • 7.5.1. Pharmaceutical Price Controls and Measures Being Implemented in South Korea
      • 7.5.1.1. KORUS FTA: The Free Trade Agreement between South Korea and the US
      • 7.5.1.2. The Free Trade Agreement between Korea and the European Union
    • 7.5.2. South Korean Generic Drugs Market: Sales Forecast 2017-2027
  • 7.6. Turkish Generic Drugs Market: Price Cuts May Impact the First Half of the Forecast Period
    • 7.6.1. Cost Cutting Measures and their Effects on Turkish Generics
    • 7.6.2. Will Turkey Become a Production Base for High Technology Products?
    • 7.6.3. Turkish Generic Drugs Market: Sales Forecast 2017-2027
    • 7.6.4. Regulatory Guidelines for Generic Drugs in Turkey
    • 7.6.5. How Effective has Turkey's Health Transformation Programme Been?

8. Leading Companies in The Generic Drugs Market, 2017-2027

  • 8.1. Generic Drugs: Continuous Expansion to Rival
    • 8.1.1. The Leading Companies in the Global Generics Market
  • 8.2. Teva
    • 8.2.1. Teva: Historical Financial and Performance Analysis, 2011-2015
    • 8.2.2. Teva Generic Drugs Sales Forecast 2017-2027
    • 8.2.3. Teva and Allergan Spin-Off Generic Drug Deal
    • 8.2.4. Allergan: Historical Financial and Performance Analysis, 2011-2015
    • 8.2.5. Allergan: Developments in Generic Drug Segment Prior Mega-Deal
      • 8.2.5.1. Exit from the Chinese Generics Market
  • 8.2.5.2. Further Entry into the Japanese Generics Market
    • 8.2.6. Teva: Generic Drugs Portfolio Analysis, 2017
      • 8.2.6.1. High-Value Generics to Drive Teva's Generics Growth?
      • 8.2.6.2. The Shift Towards Innovation
      • 8.2.6.3. Copaxone Leads Teva's Moving Focus
      • 8.2.6.4. The Threat of Generic Erosion to Teva's Products
    • 8.2.7. Teva: What Future Moves Could We Expect?
  • 8.3. Novartis
    • 8.3.1. Novartis: Historical Financial and Performance Analysis, 2011-2015
    • 8.3.2. Novartis Generic Drugs Sales Forecast 2017-2027
    • 8.3.3. Novartis Generic Drugs Portfolio Analysis, 2017
      • 8.3.3.1. Emphasis on Difficult-to-Manufacture Products
    • 8.3.4. What Does the Future Hold for Novartis' Generic Drugs Business?
  • 8.4. Mylan
    • 8.4.1. Mylan: Historical Financial and Performance Analysis, 2011-2015
    • 8.4.2. Mylan Generic Drugs Sales Forecast 2017-2027
    • 8.4.3. Mylan: Recent Developments
      • 8.4.3.1. Acquisition of Abbott's Generic Business
      • 8.4.3.2. Mylan's Growth in Manufacturing Capacity
      • 8.4.3.3. Mylan Acquires Rights to GSK's Advair, Diskus and Seretide
      • 8.4.3.4. The Race to Market Capoxone Generics
      • 8.4.3.5. Strategic Acquisition of Agila Expands Mylan's Injectables Business
    • 8.4.4. Mylan's Collaborative Efforts
      • 8.4.4.1. Biosimilar Collaboration with India's Biocon
      • 8.4.4.2. Biosimialr Collaborations with Momenta
    • 8.4.5. What Does the Future Hold for Mylan's Generic Drugs Business?
  • 8.5. Pfizer
    • 8.5.1. Pfizer: Historical Financial and Performance Analysis, 2011-2015
    • 8.5.2. Pfizer's Restructuring Strategy
    • 8.5.3. Pfizer's Done Deal with Hospira
    • 8.5.4. Pfizer Generic Drugs Sales Forecast 2017-2027
    • 8.5.5. Hospira: A Brief Overview of Operations
    • 8.5.6. Hospira: Historical Financial and Performance Analysis 2011-2015
    • 8.5.7. Hospira: Recent Developments
      • 8.5.7.1. Hospira's Expansion through Strategic Acquisitions Hospira: Manufacturing Concerns and Remediation Efforts
    • 8.5.8. Future Prospects for Pfizer's Generic Business
      • 8.5.8.1. The Pfizer-Allergan Deal Falls Through
      • 8.5.8.2. Activities of Allergan (Actavis) Prior to Mega-Merger
      • 8.5.8.3. Actavis' Work on Biosimilars
  • 8.6. Abbott
    • 8.6.1. Abbott: Historical Financial and Performance Analysis, 2011-2015
    • 8.6.2. Abbott Generic Drugs Sales Forecast 2017-2027
    • 8.6.3. Abbott: Recent Developments
      • 8.6.3.1. Abbott after the Spin-Off of AbbVie - The Established Products Business Segment
      • 8.6.3.2. Acquisition of Solvay Pharmaceutcials and Piramal Healthcare Solutions
      • 8.6.3.3. Acquisition of CFR Pharmaceuticals Opens New Markets
    • 8.6.4. What Does the Future Hold for Abbott's Generic Drugs Business?
  • 8.7. Sun Pharma
    • 8.7.1. Sun Pharma's Business Areas
    • 8.7.2. Sun Pharma: Historical Financial and Performance Analysis, 2011-2015
    • 8.7.3. Sun Pharma Generic Drugs Sales Forecast 2017-2027
    • 8.7.4. Sun Pharma-Ranbaxy Acquisition
  • 8.8. Aspen
    • 8.8.1. Aspen: Historical Financial and Performance Analysis, 2011-2015
    • 8.8.2. Aspen Generic Sales Forecast 2017-2027
    • 8.8.3. Aspen: Recent Developments
      • 8.8.3.1. Aspen Acquires Merck MSD's Dutch API Plant
      • 8.8.3.2. Acquisition of GSK's Anti-Thrombosis Brands
    • 8.8.4. Future Outlook for Aspen's Generic Business
  • 8.9. Fresenius Kabi
    • 8.9.1. Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015
    • 8.9.2. Fresenius Kabi Generic Drugs Sales Forecast 2017-2027
    • 8.9.3. InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
    • 8.9.4. Fresenius Kabi's Joint Venture with PT Soho Global Health
    • 8.9.5. Future Prospects for Fresenius Kabi's Generics Business
  • 8.10. Sanofi
    • 8.10.1. Sanofi: Historical Financial and Performance Analysis, 2011-2015
    • 8.10.2. Sanofi Generic Sales Forecast 2017-2027
    • 8.10.3. Sanofi's Response to Lantus Competition
      • 8.10.3.1. Emerging Market Acquisitions
    • 8.10.4. Sanofi's Strategies to Develop Generic Sales

9. Qualitative Analysis of the Generic Drugs Market, 2017-2027

  • 9.1. Market Factors Influencing the Global Generic Drugs Market
  • 9.2. SWOT Analysis of the Global Generic Drugs Market, 2017-2027
    • 9.2.1. Strengths
      • 9.2.1.1. Improving Clarity around Regulatory Processes
      • 9.2.1.2. The Continuous Government Support for Generic Manufacturers - Precursors for Innovation
      • 9.2.1.3. Higher Pace of Growth Compared with Innovative Pharma
      • 9.2.1.4. Globalisation and Its Impact on Manufacturing Capabilities
    • 9.2.2. Weaknesses
      • 9.2.2.1. Safety and Quality Concerns in the Manufacturing Process
      • 9.2.2.2. The Non-Uniformity of Excipients
      • 9.2.2.3. The Uncertainty around Patent Extensions and Exclusivities
      • 9.2.2.4. Sceptical Physicians and the Negative Consumer Perception of Generics
      • 9.2.2.5. Inefficiencies in Certain Regulatory Approval Processes
    • 9.2.3. Opportunities
      • 9.2.3.1. Higher Value Biosimilars and Branded Generics
      • 9.2.3.2. Patent Expiries Creating Opportunities
      • 9.2.3.3. Changing Scio-Economic Conditions Impacting Generic Drugs Demand
      • 9.2.3.4. Emerging Markets - Expected to Drive Generics Volume Growth over Time
    • 9.2.4. Threats
      • 9.2.4.1. Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
      • 9.2.4.2. The Complexity Surrounding Patents and Patents Expiries
      • 9.2.4.3. Pharmacies and Healthcare Payer Consolidations
      • 9.2.4.4. Possible Impacts of a Declining Pool
  • 9.3. Porter's Five Force Analysis of the Global Generic Drugs Market, 2017-2027
    • 9.3.1. Power of Buyers: Medium
    • 9.3.2. Power of Suppliers: Low
    • 9.3.3. Rivalry among Competitors: High
    • 9.3.4. Threat of New Entrants: High
    • 9.3.5. Threat of Substitutes: Low

10. Conclusions

  • 10.1. Overview of Current Market Conditions and Market Forecast, 2017-2027
  • 10.2. Generic Drugs as a Strategic Tool in Healthcare
  • 10.3. Major Drivers of Growth for Generic Drugs, 2017-2027
  • 10.4. The Regulatory Landscape for Generic Drugs
  • 10.5. Leading Generic Drug Manufacturers
  • 10.6. Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2027
  • 10.7. Generic Penetration by Volume in Leading National Markets
  • 10.8. What Does the Future Hold for the Global Generic Drugs Market?

11. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1: Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2015-2027 (Redacted Data)
  • Table 2.1: Types of Drug Names, 2017
  • Table 2.2: Currency Exchange Rates, 2016
  • Table 3.1: The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2015 and 2016
  • Table 3.2: The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2015 and 2016
  • Table 3.3: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 3.4: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2027
  • Table 3.5: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015, 2021, and 2027
  • Table 3.6: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
  • Table 3.6: (cont'd) The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
  • Table 3.7: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021, 2021-2027, 2015-2027
  • Table 3.8: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015, 2021, and 2027
  • Table 3.9: lobal Generic Drugs Market Drivers and Restraints, 2015-2027
  • Table 4.1: US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
  • Table 4.2: US Generic Drugs Market Drivers and Restraints, 2017-2027
  • Table 4.3: US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.1: The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2015 and 2016
  • Table 5.2: EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.3: The EU5 Generic Drugs Market: Market Share (%) by Country, 2015, 2021, 2027
  • Table 5.4: The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.5: German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 5.6: German Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Table 5.7: The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.8: UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 5.9: UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
  • Table 5.10: The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.11: French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 5.12: French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Table 5.13: The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 5.14: Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2017
  • Table 5.15: Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Table 5.16: The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2015-2027
  • Table 5.17: Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 5.18: Spanish Generic Drugs Market: Generic Penetration of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Table 6.1: The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.2: Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 6.3: Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
  • Table 6.4: The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.5: Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Table 6.6: Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Table 6.7: The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 6.8: Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2016, 2021 & 2027
  • Table 7.1: The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 7.2: The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 7.3: The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 7.4: The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 7.5: The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.1: Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2015 and 2016
  • Table 8.2: Teva: Company Overview, 2015-2016
  • Table 8.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.4: Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.5: Allergan: Company Overview 2015-2016
  • Table 8.6: Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.7: Novartis: Overview, 2015-2016
  • Table 8.8: Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.9: Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.10: Mylan: Company Overview, 2015-2016
  • Table 8.11: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.12: Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.13: Pfizer: Company Overview, 2015-2016
  • Table 8.14: Pfizer: Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.15: Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.16: Hospira: Company Overview, 2014-2015
  • Table 8.17: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Table 8.18: Allergan: Company Overview, 2015-2016
  • Table 8.19: Abbott: Company Overview, 2015-2016
  • Table 8.20: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.21: Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.22: Sun Pharmaceuticals: Company Overview, 2015-2016
  • Table 8.23: Sun Pharma: Historical Generic Drugs Sales ($bn), 2011-2015
  • Table 8.24: Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.25: Aspen: Company Overview, 2015-2016
  • Table 8.26: Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
  • Table 8.27: Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.28: Fresenius Kabi: Company Overview, 2015-2016
  • Table 8.29: Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015
  • Table 8.30: Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 8.31: Sanofi: Company Overview, 2015-2016
  • Table 8.32: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 8.33: Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
  • Table 9.1: SWOT Analysis of the Generic Drugs Market, 2017-2027
  • Table 9.2: World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2015-2027
  • Table 10.1: Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2015, 2021 and 2027
  • Table 10.2: Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2016
  • Table 10.3: Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2015, 2021 and 2027
  • Table 10.4: US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Table 10.5: BRIC Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Table 10.6: Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Table 10.7: Generic Drug Penetration by Volume in Leading National Markets (%), 2016

List of Figures

  • Figure 1.1: Global Generic Drugs Market Segmentation
  • Figure 2.1: EU Data Exclusivity for Generics: Possible Scenarios, 2016
  • Figure 3.1: The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
  • Figure 3.2: The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2016
  • Figure 3.3: The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
  • Figure 3.4: The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2016
  • Figure 3.5: Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2015-2027
  • Figure 3.6: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015
  • Figure 3.7: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2021
  • Figure 3.8: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2027
  • Figure 3.9: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021
  • Figure 3.10: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2021-2027
  • Figure 3.11: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2027
  • Figure 3.12: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015
  • Figure 3.13: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2021
  • Figure 3.14: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2027
  • Figure 4.1: US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
  • Figure 4.2: US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
  • Figure 5.1: The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
  • Figure 5.2: The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2016
  • Figure 5.3: Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Figure 5.4: The EU5 Generic Drugs Market: Market Share (%) by Country, 2015
  • Figure 5.5: The EU5 Generic Drugs Market: Market Share (%) by Country, 2021
  • Figure 5.6: The EU5 Generic Drugs Market: Market Share (%) by Country, 2027
  • Figure 5.7: The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 5.8: German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Figure 5.9: German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
  • Figure 5.10: The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 5.11: UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Figure 5.12: UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
  • Figure 5.13: The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 5.14: French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Figure 5.15: French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical sales (%) and AGR (%), 2001-2016
  • Figure 5.16: The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 5.17: Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Figure 5.18: Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Figure 5.19: The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2015-2027
  • Figure 5.20: Spanish Generic Drugs Market: Generic Penetration by Volume of Prescriptions (%) and AGR (%), 2001-2016
  • Figure 5.21: Spanish Generic Drugs Market: Generic Penetration by Proportion of Pharmaceutical Sales (%) and AGR (%), 2001-2016
  • Figure 6.1: China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Figure 6.2: The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 6.3: Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
  • Figure 6.4: Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
  • Figure 6.5: The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
  • Figure 6.6: Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2001-2016
  • Figure 6.7: Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%) 2001-2016
  • Figure 6.8: The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
  • Figure 6.9: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2016
  • Figure 6.10: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2021
  • Figure 6.11: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2027
  • Figure 7.1: Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Figure 7.2: The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
  • Figure 7.3: The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 7.4: The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 7.5: The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
  • Figure 7.6: The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.1: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
  • Figure 8.2: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016
  • Figure 8.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.4: Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.5: Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.6: Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.7: Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.8: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.9: Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.10: Pfizer: Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.11: Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.12: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.13: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.14: Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.15: Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2011-2015
  • Figure 8.16: Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.17: Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.18: Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
  • Figure 8.19: Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.20: Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2011-2015
  • Figure 8.21: Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.22: Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 8.23: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 8.24: Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
  • Figure 9.1: World 65+ Population Forecast: Size (m) and AGR (%), 2015-2027
  • Figure 9.2: Porter's Five Force Analysis of the Global Generic Drugs Market, 2017
  • Figure 10.1: Global Generic Drugs Market Forecast: Revenue ($bn), 2015, 2021 and 2027
  • Figure 10.2: US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Figure 10.3: BRIC Generic Drugs Market Forecast: ($bn), 2015-2027
  • Figure 10.4: Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
  • Figure 10.5: Generic Drug Penetration by Volume in Leading National Markets (%), 2016

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • Alcon (Novartis)
  • Allergan (Actavis)
  • Amgen
  • Anda Inc
  • APP Pharmaceuticals
  • Arrow Group (Actavis)
  • Ascent Pharmahealth (Actavis)
  • ASKA Pharmaceuticals
  • Aspen
  • AstraZeneca
  • Bergamo (Amgen)
  • Bioniche Pharma (Mylan)
  • BMP Sunstone (Sanofi)
  • CFR Pharmaceuticals (Abbott)
  • Cipla
  • Dabur Pharma (Fresenius Kabi)
  • Daiichi Sankyo
  • Dalim BioTech
  • Dr Reddy's Laboratory
  • Ebewe Pharma (Novartis)
  • Eden Biopharm Group
  • Egis
  • Elder Pharmaceuticals (Torrent Pharmaceuticals)
  • Eli Lilly
  • Elyson Pharmaceuticals
  • EMS Sigma Pharma
  • Eurofarma Laboratories
  • Farmacias Similares
  • Fenwal (Fresenius Kabi)
  • Forest Laboratories (Actavis)
  • Foshan Chanbende Development
  • Fougera Pharmaceuticals (Novartis)
  • Fresenius Kabi
  • Fresenius SE & Co
  • Fuji Pharma
  • Gedeon Richter
  • Genfar S.A (Sanofi)
  • Genzyme (Sanofi)
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Greenstone (Pfizer)
  • Grupo Sanborns
  • Grupo Uriach
  • Hospira (Pfizer)
  • IDEV Technologies (Abbott)
  • Ilsung Pharmaceuticals
  • InnoPharma Inc
  • Itero Biopharmaceuticals
  • Janssen
  • Javelin Pharmaceuticals (Hospira)
  • Kmart
  • KMS Pharmaceutical
  • Kowa Pharmaceuticals
  • Krka
  • Labesfal Genéricos (Fresenius Kabi)
  • Laboratorio Sanderson (Fresenius Kabi)
  • Laboratorios Best
  • Laboratorios Kendrick (Sanofi)
  • Lek (Novartis)
  • Lupin
  • Mayne Pharma (Hospira)
  • Medley (Sanofi)
  • Merck KGaA
  • MN Pharma (Amgen)
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nexus Pharmaceuticals
  • Nichi-Iko
  • Nippon Chemiphar
  • Novartis (Sandoz)
  • Novo Nordisk
  • OptiMedica (Abbott)
  • Orchid Chemicals & Pharmaceuticals
  • Oriel Therapeutics (Novartis)
  • Parenteral Drugs India Ltd
  • Perrigo
  • Pfizer
  • Piramal (Abbott Laboratories)
  • Pliva (Teva)
  • PT Soho Global Health
  • Ranbaxy (Sun Pharmaceuticals)
  • Rimsa
  • Roche
  • Sabex (Novartis)
  • Sanofi
  • Sawai Pharmaceuticals
  • Schein Pharmaceutical (Actavis)
  • Shelys (Aspen)
  • Sigma Pharmaceuticals (Aspen)
  • Solvay Pharmaceuticals (Abbott)
  • Specifar Pharmaceuticals (Actavis)
  • STADA Arzneimittel
  • Sun Pharma
  • Synthon
  • Takeda
  • Taiyo Pharmaceuticals
  • Teuto Brasileiro (Pfizer)
  • Teva
  • The Laboratory of Analytical Services International Ltd
  • Towa
  • UDL Laboratories
  • Uteron Pharma (Actavis)
  • Valeant Pharmaceuticals
  • Wal-Mart
  • Warner Chilcott (Actavis)
  • Wockhardt
  • Wyeth (Pfizer)
  • Zentiva (Sanofi)
  • Zhejiang Chiral Medicine Chemicals Co. Ltd
  • Zhejiang Hisun Pharmaceutical
  • Zydus Cadila
  • List of Organizations Mentioned in the Report
  • Assogenerici [Italy]
  • Blue Cross Blue Shield Association (BCBSA) [US]
  • British Generic Manufacturers Association (BGMA)
  • Caisse Nationale de l'Assurance Maladie (CNAM) [France]
  • Center for Drug Evaluation and Research (CDER) [US]
  • Centers for Medicare and Medicaid Services [US]
  • China Food and Drug Administration (CFDA)
  • COFEPRIS [Mexico]
  • Competion and Markets Authority (CMA) [UK]
  • Congressional Budget Office (CBO) [US]
  • European Commission
  • European Generics Medicines Association (EGA)
  • European Medicines Agency (EMA)
  • European Patent Office (EPO)
  • Federal Trade Commission (FTC) [US]
  • Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
  • Food and Drugs Administration (FDA) [US]
  • Gesundheitsberichterstattung des Bundes (Federal Health Monitoring System, Germany)
  • General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
  • General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
  • Medicine and Healthcare products Regulatory Agency (MHRA)
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Ministry of Human Resources and Social Security (MOHRSS)
  • National Development and Reform Commission (NDRC)
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority [India]
  • Pan American Health Organization (PAHO)
  • Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
  • Queen Mary University of London
  • Servicio Sanitario Nazionale (SSN) [Italy]
  • United Nations' Department of Economic and Social Affairs
  • US Generic Pharmaceutical Association (GPhA)
  • Veropharm (Abbott)
  • World Health Organization (WHO)
  • World Trade Organisation (WTO)
Back to Top